case 1:17-cv-02540 document 1-1 filed 04/10/17 page 1 of ... · appendix a # date writer/publisher...

Appendix A

# Date Writer/Publisher Pseudonym Promoter Issuer ClientWebsite Where

PublishedTitle

Omission re: Receipt of Payment (Y/N)

Affirmative Misrep. re: Receipt of

Payment (Y/N)

1 2011.08.16 Cassano, Vincent VFC's Stock House Lavos AMPESeeking Alpha

Ampio Pharmaceuticals’ Bevy of Repositioned Products Could Make a Splash in Health Care

Y Y


Biotech‐on‐The‐Verge Ampio Pharmaceuticals Bolsters Its Management

Y Y


Ampio Rebounds As Study Results Published in Europe

Y N


Ampio Pharmaceuticals: Catalysts/Recent Slide May Have Opened Up A Buying

OpportunityY N


Ampio’s Rebound Goes Hand‐In‐Hand With Pipeline Progress

Y N


Another Round of Milestone News Solidifies Ampio’s Pipeline Potential

Y N

7 2011.11.08 Ramey, Stephen Chemistfrog Lavos/Lidingo IMUCSeeking Alpha

ImmunoCellular Therapeutics' Cancer Stem Cell Drug Garnering Much Attention

Y N


3 Cancer Immunotherapy Biotechs with Catalysts for 2012

Y N

ADMD = Advanced Medical Isotope Corporation; AMPE = Ampio Pharmaceuticals, Inc.; APHY = Assured Pharmacy, Inc. (now bankrupt); ARTH = Arch Therapeutics, Inc.; ENZ = Enzo Biochem, Inc.; GALE = Galena Biopharma, Inc.; IMUC = Immunocellular Technologies, Ltd.; LBIO = Lion Biotechnologies, Inc.; LPTN = LPath, Inc. (now APEN; Apollo Endosurgery, Inc.); NBS = Neostem, Inc. (now CLBS; Caldrius Bioscences, Inc.); ONCS = Oncosec Medical, Inc.; STVF = Stevia First Corporation (now VBIO; Vitality Biopharma, Inc.)

1

Case 1:17-cv-02540 Document 1-1 Filed 04/10/17 of 62

Appendix A


PublishedTitle



Payment (Y/N)


9 2011.11.16 Cassano, Vincent VFC's Stock House Lavos/Lidingo LPTNSeeking Alpha

Stocks to Watch as Volatility Abounds in Europe

Y N

10 2011.11.22 Ramey, Stephen Chemistfrog Lavos/Lidingo LPTNSeeking Alpha

Lipid Signaling Could Shake Up Biotech in 2012 With Pending Lpath and Peregrine Trial Data

Y N

11 2011.12.07 Ramey, Stephen Chemistfrog Lavos/Lidingo LPTNSeeking Alpha

Lipid Signaling: The Next Evolutionary Step In Wet AMD Treatment?

Y N

12 2011.12.12 Writer 2 N/A Lavos/Lidingo LPTNSeeking Alpha

Lower R&D Budgets For Big Pharma Creating A Brighter Future For The Right Biotechs

Y N

13 2012.01.10 Cassano, Vincent VFC's Stock House Lavos/Lidingo LPTNSeeking Alpha

Stocks To Watch This Week Y N

14 2012.01.11 Ramey, Stephen Chemistfrog Lavos/Lidingo GALE, LPTNSeeking Alpha

Top Of The Class Biotechs For 2012 Y N


Pharma Leaders Emerging in Immunotherapy Approach to Fighting Glioblastoma

Y N

16 2012.01.18 Cassano, Vincent VFC's Stock House Lavos/Lidingo IMUCSeeking Alpha

Another Revival Could Be In Store for ImmunoCellular Therapeutics

Y N

2


Appendix A


PublishedTitle



Payment (Y/N)



Biopharma Stocks To Watch This Week Y N

18 2012.01.25 Ramey, Stephen Chemistfrog Lavos/Lidingo GALESeeking Alpha

Immunotherapy Cancer Trials with Key Data Due in 2012

Y N


Stocks To Watch Week of Jan. 30 Y N


Verastem IPO Validates Investor Interest in Cancer Stem Cell Approach

Y N


ImmunoCellular: Pipeline Potential and Institutional Interest Fuel Rebound

Y N

22 2012.02.01 Nichols, Brian N/A Lavos/Lidingo GALESeeking Alpha

Illogical Biotech Valuations Create Value and Value Traps

Y N


5 Pharmaceuticals On The Move Y N


Stocks to Watch Week of Feb. 6 Y N

3


Appendix A


PublishedTitle



Payment (Y/N)


25 2012.02.08 Writer 2 N/A Lavos/Lidingo GALE, IMUCSeeking Alpha

ImmunoCellular and Cancer Treatment's Next Frontier

Y N


10 Biotech Stocks with Big Potential Upside in 2012: Part Two

Y N


Weekly Stock Watch: Feb. 13 Edition Y N


Stock Watch: Immunocellular's Push Toward Two Dollars

Y N


Immunocellular Again Pushing to $2 Y N

30 2012.02.16 Nichols, Brian N/A Lavos/Lidingo IMUCSeeking Alpha

10 Biotech Stocks with Big Potential Upside in 2012: Part III

Y N

31 2012.02.21 Writer 2 N/A Lavos/Lidingo IMUCSeeking Alpha

A Roadmap for Immunotherapy Success in Oncology

Y N


Buy Biotech in Phase II for the Best Upside Y N

4


Appendix A


PublishedTitle



Payment (Y/N)


33 2012.03.01 Nichols, Brian N/A Lavos/Lidingo GALE, IMUCSeeking Alpha

Dendreon's Woes Mask the Exciting Opportunities in Immunotherapy Companies

Y N


Weekly Stock Watch: Feb 27 – March 2 Y N


Immunocellular Therapeutics: Pending Catalysts Could Spark Share Price Run

Y N


Big Pharma's Growing Appetite for Cancer Stem Cell Biotechs

Y N


Immunocellular Touches $3 on Continued Speculation

Y N


Breast Cancer Immunotherapy: A New Hope in the Fight

Y N


Weekly Stock Watch: March 12‐16 Y N


Upgrades Lead to Optimism in Cancer Stem Cell Therapy

Y N

5


Appendix A


PublishedTitle



Payment (Y/N)


41 2012.03.13 Lidingo (Nichols) A. John Hodge Lavos/Lidingo GALESeeking Alpha

Galena Looks Undervalued Considering Cancer Therapy Results

Y N

42 2012.03.19 Lidingo A. John Hodge Lavos/Lidingo GALE, IMUCSeeking Alpha

Small Cap Biotech Stocks Trading Higher Y N


Stocks to Watch: Week of March 19‐23 Y N


Galena Biopharma Preparing for a 3 Day Rally? Y N


Galena Biopharma's Patent Creates Both Immediate and Long‐Term Upside

Y N


Immunocellular Therapeutics Patent Acquisition Paradigm Shift

Y N


Immunocellular Therapeutics: Cementing Its Place as a Major Player in Cancer

ImmunotherapyY N

48 2012.03.26 Cassano, Vincent VFC's Stock House Lavos/Lidingo GALE, IMUC Seeking Alpha

Stocks to Watch: Week of March 26‐30 Y N

6


Appendix A


PublishedTitle



Payment (Y/N)


49 2012.03.26 Lidingo The Swiss Trader Lavos/Lidingo GALESeeking Alpha

Galena Biopharma: An Investor's Overview Y N


Weekly Stock Watch: March 26‐20 [sic] Y N

51 2012.03.28 Ramey, Stephen Chemistfrog Lavos/Lidingo IMUC BenzingaImmunoCellular's Intellectual Property

Steadily IncreasesY N


ImmunoCellular Therapeutics' Growing Intellectional Property Garnering Attention

Y N

53 2012.04.05 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo GALESeeking Alpha

Galena Biopharma: Risk Mitigated After Financing

Y N


Weekly Stock Watch: April 9‐13 Y N


Breaking the Mold of Oncology Drug Development

Y N


Immunocellular Therapeutics May Be Immune to a Broad Market Downturn

Y N

7


Appendix A


PublishedTitle



Payment (Y/N)



Galena and the RXI Spin‐Off Y N


Which Q1 Biotech Movers Can Build off Momentum? Part II

Y N


Which Q1 Biotech Movers Can Build Off Momentum?

Y N

60 2012.04.12 Lidingo Baldwin, Amy Lavos/Lidingo GALESeeking Alpha

Long Galena Biopharma: Creating a New Breast Cancer Treatment Alternative

Y N


Successfully Profiting from Developmental Biotech

Y N


Phase III Trial Biotechs for Investment Consideration

Y N


Stocks to Watch Mid‐Week: April 18 Y N

64 2012.04.19 Ramey, Stephen Chemistfrog Lavos/Lidingo NBSSeeking Alpha

Stem Cell Research: Which Companies Will Emerge As Frontrunners?

Y N

8


Appendix A


PublishedTitle



Payment (Y/N)


65 2012.04.19 Writer 2 N/A Lavos/Lidingo IMUCSeeking Alpha

Why the Markets Continue to Coalesce Around New Approaches to Treating Cancer

Y N

66 2012.04.21 Ramey, Stephen Chemistfrog Lavos/Lidingo NBS Benzinga Stem Cell Biotechs: A Frontrunner Emerges? Y N


Weekly Stock Watch: April 23‐27 Y N

68 2012.04.23 Nichols, Brian N/A Lavos/Lidingo NBSSeeking Alpha

Neostem: Investing in the Potential Success of Cell Therapy

Y N

69 2012.04.23 Ramey, Stephen Chemistfrog Lavos/Lidingo NBSMarket

PlaygroundNeostem Inc. (NBS) is Poised for Growth in

2012Y N


Galena Biopharma: How Long Can Big Pharma Wait?

Y N

71 2012.04.24 Ramey, Stephen Chemistfrog Lavos/Lidingo GALE, IMUC BenzingaMultiple Antigen Targeting Could Mean a

Multiple Marketing for These Immunotherapy Drugs

Y N

72 2012.04.25 Ramey, Stephen Chemistfrog Lavos/Lidingo GALE, IMUCSeeking Alpha

Multiple Antigen Targeting Could Indicate Big Potential for Immunotherapy Drugs

Y N

9


Appendix A


PublishedTitle



Payment (Y/N)


73 2012.04.27 Writer 5 Dutch Trader Lavos/Lidingo NBSSeeking Alpha

NeoStem's Comeback In The Making Y N


Weekly Stock Watch: April 30‐May 4 Y N


ImmunoCellular Therapeutics and the Benefits of a Large Exchange

Y N

76 2012.05.01 Cassano, Vincent VFC's Stock House Lavos/Lidingo IMUC Seeking Alpha

Immunocellular Therapeutics: Any Pullback May Mean Opportunity

Y N


Interviewing Mark Ahn: the Truth behind Neuvax

Y N

78 2012.05.02 Lidingo The Swiss Trader Lavos/Lidingo IMUCSeeking Alpha

Finding an Oncology Player That Will Change the Rules of the Game

Y N


Stocks to Watch: Week of May 7, 2012 Y N


Stem Cell Biotechs Report 2011 Year in Review: Part 1

Y N

10


Appendix A


PublishedTitle



Payment (Y/N)



Stem Cell Biotechs Report 2011 Year in Review: Part II

Y N

82 2012.05.07 Ramey, Stephen Chemistfrog Lavos/Lidingo ONCSSeeking Alpha

Targeted Chemotherapy: The Perfect Balance Between Safety and Efficacy?

Y N


Pre‐ASCO Interview with ImmunoCellular Therapeutics CEO Dr. Singh

Y N

84 2012.05.10 Lidingo The Swiss Trader Lavos/Lidingo NBSSeeking Alpha

5 Reasons to Buy NeoStem and 2 Catalysts Y N

85 2012.05.10 Lidingo (Nichols) A. John Hodge Lavos/Lidingo ONCSSeeking Alpha

Oncosec Medical: Developing a New Approach in Cancer Treatments

Y N


NeoStem: Trio of Catalysts? Y N


Provenge and NeuVax: A Tale of 2 Marvels Y N

88 2012.05.15 Lidingo The Swiss Trader Lavos/Lidingo NBS, ONCSSeeking Alpha

Public Offerings Create Investing Opportunities in Biotech Sector

Y N

11


Appendix A


PublishedTitle



Payment (Y/N)



Dr. Robin Smith Explaining Neostem: a True Value Play

Y N

90 2012.05.18 Lidingo The Swiss Trader Lavos/Lidingo GALE, IMUCSeeking Alpha

ASCO 2012 Abstracts: 4 Hopeful Overachievers

Y N


Galena Biopharma With Near Term ASCO Catalyst

Y N

92 2012.05.21 Lidingo (Nichols) A. John Hodge Lavos/Lidingo IMUCSeeking Alpha

Interest Growing in Cancer Stem Cell Biotechs Y N

93 2012.05.21 Lidingo Baldwin, Amy Lavos/Lidingo ONCSSeeking Alpha

Investment Choices for Melanoma Awareness Month

Y N

94 2012.05.23 Lidingo A. John Hodge Lavos/Lidingo NBSSeeking Alpha

Weighing the Benefits of Osiris's First Cell Therapy Approval

Y N


A Short Interview With Galena CEO Dr. Ahn to Address Recent Concerns

Y N


NeoStem A Chinese Takeover Candidate? Y N

12


Appendix A


PublishedTitle



Payment (Y/N)



ImmunoCellular Therapeutics' Uplisting to NYSE Could Immediately Open Many Doors

Y N

98 2012.05.30 Lidingo A. John Hodge Lavos/Lidingo ONCSSeeking Alpha

Hyper‐Novel Investments for Targeting Cancer Y N


ImmunoCellular Therapeutics ICT‐107 To Impress at ASCO 2012

Y N


Baxter and NeoStem Validating Each Other's Cell Therapies

Y N


5 Biotech Stocks that Could Be Included in the Russell 2000

Y N

102 2012.06.04 Writer 5 Dutch Trader Lavos/Lidingo ONCSSeeking Alpha

Alternative Cancer Therapies Currently Overlooked by Investors

Y N


NeoStem: an Investment in Both Stem Cell and Immunotherapy

Y N

104 2012.06.05 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo GALESeeking Alpha

ASCO with Upgrades: Create Catalysts for Growth

Y N

13


Appendix A


PublishedTitle



Payment (Y/N)



Russell Index Additions to Create Upside While Shares are Acquired in Open Market

Y N


Orphan Drug Designation Biotechs for Investment Consideration

Y N


NeoStem and the Chinese Healthcare Sector Y N


Dendreon: Room for Improvement Y N


Galena's Big Data Insinuates Big Upside, While Valuation Presents Minimal Downside

Y N


Neostem's $50 Million Sale Lifts Restraints, Allows the Company to Thrive

Y N


4 Stocks that Could Trade Higher in the Coming Weeks

Y N

112 2012.06.18 Lidingo The Swiss Trader Lavos/Lidingo IMUCSeeking Alpha

Immunotherapy Comes of Age at ASCO 2012 Y N

14


Appendix A


PublishedTitle



Payment (Y/N)



3 Small Cap Pharmas with Major Second Half 2012 Catalysts

Y N

114 2012.06.19 Lidingo A. John Hodge Lavos/Lidingo ADMDSeeking Alpha

Radiation Treatments Look Poised To Grow In The Immediate Future

Y N


6 Stocks Trading with Momentum‐‐Can it Continue?

Y N

116 2012.06.25 Lidingo (Nichols) A. John Hodge Lavos/Lidingo NBSSeeking Alpha

NeoStem: Correcting with Market Leading Gains

Y N

117 2012.06.27 Lidingo A. John Hodge Lavos/Lidingo IMUCSeeking Alpha

ImmunoCellular: Cancer is Smart, But Could an Experimental Cancer Vaccine Be Smarter?

Y N

118 2012.07.03 Lidingo Baldwin, Amy Lavos/Lidingo NBSSeeking Alpha

Baxter, NeoStem Duel for Next‐Gen Heart Disease Stem Cell Therapy

Y N

119 2012.07.03 Lidingo The Swiss Trader Lavos/Lidingo ONCSSeeking Alpha

Melanoma Treatments Look to Benefit From Large Market

Y N


Dendritic Cell Evolution: Investment Potential Y N

15


Appendix A


PublishedTitle



Payment (Y/N)



Cardiovascular Cell Therapies to Put Pressure on U.S. Regulators

Y N


Q1 Biotech Movers Making a Comeback Y N


Russell Rebalancing Leaves NeoStem Trading Higher to Reflect Good News

Y N


Intellectual Property of a Biotech: An Analysis Y N


Neostem Continues to Rally Behind Its Key Developments

Y N


Investment Potential In Electroporation Companies

Y N

127 2012.07.17 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo IMUCSeeking Alpha

3 Innovative Cancer Treatments . . . But Which Is the Best Bet?

Y N


New Legislation Speeds up FDA Approval Process for Immunocellular Therapeutics and

Other Innovating TherapiesY N

16


Appendix A


PublishedTitle



Payment (Y/N)


129 2012.07.19 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo NBSSeeking Alpha

A Big Win for NeoStem Y N


ImmunoCellular Therapeutics: Explaining the Benefits of a Multiple Antigen Targeting

ApproachY N


Week of July 23rd Comprised of Huge Pharmaceutical Catalysts

Y N


Heavy Volume May Mean Heavier Profits in Small Biopharmaceutical Stocks

Y N

133 2012.07.24 Ramey, Stephen Chemistfrog Lavos/Lidingo ADMDSeeking Alpha

Investments in Radiotherapy Can Prevent Decay in Your Portfolio

Y N

134 2012.07.24 Lidingo Kawabe, Henry Lavos/Lidingo GALESeeking Alpha

Cancer Vaccines Show Positive Results for Both Patients and Investors

Y N


Significant Investment Potential In the Fast Growing Metastatic Melanoma Market

Y N

136 2012.07.26 Lidingo Baldwin, Amy Lavos/Lidingo IMUCSeeking Alpha

5 Momentum Stocks With Pullbacks That Could Be Your Opportunity

Y N

17


Appendix A


PublishedTitle



Payment (Y/N)



Neostem's Promising VSEL Developments are Good Signs for the Future of Cell Therapy

Y N


Small Cap Adjuvants for Cancer Treatment Y N


Are Stem Cells Becoming the Next Bull Market in the Biotech Space?

Y N


Radioisotopes: New Hope Using an Old Therapy

Y N


Dendreon Approaching End of Road, While Other Immunotherapies Thrive

Y N


Risk in the Pharmaceutical Sector Overemphasized in the Past Week

Y N

143 2012.08.08 French, Chris Cris Frangold Lavos/Lidingo IMUCSeeking Alpha

3 Diverse Investment Grade Pharmaceuticals to Consider Today

Y N


Stem Cell Sector Validating Itself with Exciting First Half 2012

Y N

18


Appendix A


PublishedTitle



Payment (Y/N)


145 2012.08.09 French, Chris Cris Frangold Lavos/Lidingo NBSSeeking Alpha

3 Biotech Companies to Consider for Stem Cell Exposure

Y N


Riding the Ups and Downs Among Pharmaceutical Companies

Y N


Stem Cell Therapy Gaining Ground and Investor Attention

Y N

148 2012.08.13 French, Chris Cris Frangold Lavos/Lidingo ONCSSeeking Alpha

3 Innovative Biotech Stocks to Consider Today Y N

149 2012.08.14 Nichols, Brian N/A Lavos/Lidingo ADMDSeeking Alpha

Isotopes, Shortages, Solutions & The Growing Demand of Cancer Treatment

Y N


ICT‐107 Into Perspective Part 1 Y N


Galena Showing Similarities to Immunogen and Looks to Follow Its Path

Y N

152 2012.08.17 French, Chris Cris Frangold Lavos/Lidingo ADMDSeeking Alpha

3 Biotech Stocks Showing Promise in Radiotherapy Treatment

Y N

19


Appendix A


PublishedTitle



Payment (Y/N)


153 2012.08.17 Lidingo Kawabe, Henry Lavos/Lidingo STVFSeeking Alpha

Big Bottlers Coca Cola and PepsiCo Bring Stevia From Health Food Stores to

MainstreamY N

154 2012.08.19 Writer 2 N/A Lavos/Lidingo STVFSeeking Alpha

The Future Looks Sweet for Monsanto as New Opportunities in Agribusiness Emerge

Y N

155 2012.08.20 Cassano, Vincent VFC's Stock House Lavos/Lidingo NBSSeeking Alpha

Weekly Stock Watch for August 20 Y N


3 Companies with Promising Investment Potential in Brachytherapy Treatment for

CancerY N


Digging Deeper into Less‐Invasive Cancer Treatment Investments

Y N


Cell Therapy Outlook Starting to Match Clinical Results

Y N

159 2012.08.22 Lidingo The Swiss Trader Lavos/Lidingo ADMDSeeking Alpha

White House Stance on Medical Isotopes May Leave Foreign Producers Nuked

Y Y

160 2012.08.22 Lidingo Olsen, Sven Lavos/Lidingo STVFMarket

PlaygroundCan Stevia First Corporation (STVF) Cash In on

a $60 Billion Market?Y N

20


Appendix A


PublishedTitle



Payment (Y/N)



A Diverse Group of Pharmaceuticals With Good Upside Potential

Y Y


Assessing Galena Biopharma's Stock Upgrade and Reflecting on Other Upgrades

Y Y


Investments in Society's Sweet Tooth: Old And New Ideas

Y Y

164 2012.08.27 Cassano, Vincent VFC's Stock House Lavos/Lidingo ADMD, ONCSSeeking Alpha

Weekly Stock Watch: Week of 27 August Y Y

165 2012.08.27 French, Chris Mel Daris Lavos/Lidingo NBSSeeking Alpha

Consider These Three Biotech Stocks for Potential Growth

Y Y

166 2012.08.29 Lidingo Baldwin, Amy Lavos/Lidingo NBS, ONCSSeeking Alpha

Biotech: Mega‐Caps Show Investors the Way Y Y


4 Biotech Stocks with Large 2012 Gains that Still Present Significant Upside

Y Y

168 2012.09.04 Cassano, Vincent VFC's Stock House Lavos/LidingoNBS, ONCS, ADMD

Seeking Alpha

Weekly Stock Watch: Week of 4 September Y Y

21


Appendix A


PublishedTitle



Payment (Y/N)



A Gold Mine in Biotechnology: The Companies Poised to Benefit

Y Y

170 2012.09.05 Corenman, Joel Woods, Glen S. Lavos/Lidingo STVFSeeking Alpha

Starbucks Adding Stevia to Their Energy Drinks May be a Boost for Stevia Growers

Y Y

171 2012.09.05 French, Chris Cris Frangold Lavos/Lidingo ADMDSeeking Alpha

Diverse Stocks in Modern Radiotherapy Y Y


Developments over the Next Year that Could Change NeoStem

Y Y


Amarin and NeoStem: 2 Companies Making Major Moves This Week

Y Y

174 2012.09.06 French, Chris Cris Frangold Lavos/Lidingo ONCSSeeking Alpha

3 Investments in Targeted Cancer Treatment Y Y

175 2012.09.07 Lidingo Kawabe, Henry Lavos/Lidingo STVFMarket

PlaygroundSugar and Stevia May Be the Perfect Blend for

Consumers, Companies and InvestorsY N


Stem Cell Therapy: The Black and White Therapies of the Space

Y Y

22


Appendix A


PublishedTitle



Payment (Y/N)



3 Companies With Exciting Phase II Trial Data Close Out 2012

Y Y

178 2012.09.10 Lidingo Ang Nguyen Lavos/Lidingo STVFSeeking Alpha

3 Companies With Promising Growth Potential from Stevia

Y Y

179 2012.09.11 Ramey, Stephen Chemistfrog Lavos/Lidingo ADMD, GALESeeking Alpha

Cancer Treatment Need is the Mother of Novel Solutions

Y Y

180 2012.09.17 Corenman, Joel Woods, Glen S. Lavos/Lidingo ADMDSeeking Alpha

Isotope Manufacturing Companies Step Up as Aging Nuclear Reactors and Government

Policies Threaten Nuclear MedicineY Y


Biotechnology: Valuation Doesn't Always Indicate Value

Y Y


NeoStem: A Promising Investment Candidate in Stem Cell Treatment

Y Y

183 2012.09.18 Lidingo A. John Hodge Lavos/Lidingo GALE, ONCSSeeking Alpha

Promising Development‐Phase Pharmas Leading the Fight Against Cancer

Y Y


Neuralstem Reminds Investors of Stem Cell Rewards and Risk

Y Y

23


Appendix A


PublishedTitle



Payment (Y/N)



Multi‐Stage Pharmaceuticals With Investment Potential in the War on Cancer

Y Y


3 Pharmaceuticals Pursuing Non‐Surgical Approaches to Combating Cancer

Y Y

187 2012.09.24 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo NBSSeeking Alpha

The Promising, Cheap, and Growing Cell Therapy Arena Continues to Outperform the

MarketY Y

188 2012.09.26 Lidingo Woods, Glen S. Lavos/Lidingo STVFMarket

Playground

Stevia First Corp. (STVF) Flexes its Muscles with Two Means for Producing Valuable Stevia

SweetenerY N


4 Share Price Dips That Might Only Be Temporary

Y Y


Interview with OncoSec CEO Punit Dhillon Y Y


Assessing Peregrine and Seeking Upside in the Space

Y Y

192 2012.10.01 Lidingo (Nichols) Trading Maven Lavos/Lidingo STVFSeeking Alpha

PureCircle Could Need More Production to Meet Stevia Demand

Y Y

24


Appendix A


PublishedTitle



Payment (Y/N)



Watch for Short‐Term Gains in Shares of Neostem

Y Y

194 2012.10.04 Lidingo Olsen, Sven Lavos/Lidingo STVFMarket

Playground

NYC's Curb on Oversized Sugary Drinks May Lead Fast Food Operators to Find Healthier

Alternatives to SugarY N


6 Stocks on The Move This Week Y Y


4 Biotech Stocks with Large 2012 Gains Still Present Significant Upside ‐ Revisited

Y Y

197 2012.10.07 Lidingo (Nichols) Kawabe, Henry Lavos/Lidingo NBSSeeking Alpha

NeoStem: The Best Upside in An Innovating Space

Y Y

198 2012.10.08 Lidingo (Nichols) wise4stocks Lavos/Lidingo ONCSYahoo Finance

2 delivery systems make OncoSec standout [sic] because...

Y N


Halloween‐Like Fears Influence Small Pharma Trading Techniques for 4Q 2012

Y Y


Clinical Data Separate 3 Hopeful Cancer Candidates

Y Y

25


Appendix A


PublishedTitle



Payment (Y/N)


201 2012.10.10 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo NBS, ONCSSeeking Alpha

5 Biotech Companies with Major Market‐Moving Announcements to Start the Week

Y Y

202 2012.10.11 Cassano, Vincent VFC's Stock House Lavos/Lidingo ONCSSeeking Alpha

5 Mid‐Week Stocks On The Move Y Y

203 2012.10.11 Lidingo Ang Nguyen Lavos/Lidingo STVF, ADMDSeeking Alpha

3 Companies that Could Soar on Massive Stevia Market Opportunities

Y Y


Weekly Stock Watch, Week Of 15 October Y Y

205 2012.10.16 French, Chris Mel Daris Lavos/Lidingo STVFSeeking Alpha

3 Agriculture Stocks to Consider for Exposure to Stevia

Y Y


Nobel Prize Validates Recent Stem Cell Headlines

Y Y

207 2012.10.18 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo GALE, ONCSSeeking Alpha

5 Big Time Biotech Movers on Wednesday Y Y


Weekly Stock Watch for October 22, 2012 Y Y

26


Appendix A


PublishedTitle



Payment (Y/N)



Revisiting the Investment Potential in Electroporation Companies

Y Y


3 Companies with Promising New Cancer Treatments

Y Y

211 2012.10.23 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo NBSSeeking Alpha

Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher

Y Y


Investors Take Note: Dr. Oz Touts Stevia as The Best of the Sugar Alternatives

Y Y

213 2012.10.24 Lidingo Chemistfrog Lavos/Lidingo STVFSeeking Alpha

COMMENT

Comment on Investors Take Note: Dr. Oz Touts Stevia as Best of the Sugar Alternatives

Y N

214 2012.10.25 Lidingo A. John Hodge Lavos/Lidingo NBS, ONCSSeeking Alpha

Beyond Traditional Drugs: Investments in Stem Cell, Medical Devices and Agent

AdministrationY Y


Weekly Stock Watch, Week Of 29 October Y Y


Not‐So‐Scary Watch List for Week of Halloween 2012

Y Y

27


Appendix A


PublishedTitle



Payment (Y/N)



Investment Potential In Pharmaceutical CMO Growth Acceleration

Y Y


Recent Research and Galena's New Data May Lead to an Advance in Standards of Care

Y Y

219 2012.11.01 Nichols, Brian N/A Lavos/Lidingo ONCSSeeking Alpha

Recent Biotech Price Dips Make Great Entries for Investors

Y Y


After a Data‐Packed October, What Will November bring for NeoStem?

Y Y


3 Companies with Investment Potential in Targeting Cancer

Y Y


A Change in Supply to Meet Isotope Demand Y Y

223 2012.11.05 Corenman, Joel Woods, Glen S. Lavos/Lidingo GALESeeking Alpha

Investments In the Fight Against Cancer: The Analysts’ Choices

Y Y


NeoStem CEO Dr. Smith Talks PCT Potential and Explains Recent Bullish Developments

Y Y

28


Appendix A


PublishedTitle



Payment (Y/N)



Monster Beverage to Follow the Lead of Green Mountain Coffee Roasters

Y Y


Neostem to Create Value with Billion Dollar Potential

Y Y


Developing Synergistic Relationship Between Sugar Manufacturers and Stevia Could Prove

to Have High Investment PotentialY Y


3 Acquisitions in Biotechnology that Could Occur in the Next Year

Y Y


Galena Biopharma: Catalysts Have Led Its Stock Higher

Y Y


Upcoming Melanoma Conference is an Excellent Source of Small Pharma Investor

InformationY Y


Nordion's Future Does Not Look Bright Y Y


An Exciting Week in Cell Therapy Y Y

29


Appendix A


PublishedTitle



Payment (Y/N)


233 2012.11.12 Lidingo Trading Maven Lavos/Lidingo STVFSeeking Alpha

Companies See Green in Stevia Y N


The Stem Cell Sector Further Validates Itself with a Successful Q3

Y Y


Recent Data Presented at Melanoma Conference Offers Hope for Patients, Research

for InvestorsY Y

237 2012.11.16 Lidingo Kawabe, Henry Lavos/Lidingo STVFMarket

Playground

Stevia First Corp. (STVF) Utilizing Fermentation Techniques to Produce High Quality Stevia at a

Lower CostY N


Breaking Barriers in Cardiovascular Treatments

Y Y

239 2012.11.19 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo ONCSSeeking Alpha

4 Speculative Investments You Might Want to Consider

Y Y

240 2012.11.21 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo NBSSeeking Alpha

NeoStem Awarded $1.2 Million Grant for VSEL Development

Y Y


Distinguishing Fad from Trend in Gluten Free and Stevia Markets May Expose Profitable

Investment OpportunitiesY Y

30


Appendix A


PublishedTitle



Payment (Y/N)



3 Difficult‐to‐Understand Trends in Biotechnology

Y Y

243 2012.11.26 Lidingo Kawabe, Henry Lavos/Lidingo ADMD, GALESeeking Alpha

Novel Immunotherapy and Delivery Systems Targeting Cancer May Target Gains for

InvestorsY Y


Q3 2012 Pharma Company Updates Indicate Upcoming Catalysts

Y Y


Acadia Pharmaceuticals and Galena Biopharma: What a Difference a Trial Design

Can MakeY Y

234 2012.11.29 Lidingo (Nichols)N/A (article does not include author

name)Lavos/Lidingo NBS Benzinga

Three Companies with Recent Successful Animal‐Based Studies Could Indicate Solid

UpsideY N


Small Market Cap Pharmaceuticals with Large Catalysts Looming in 2013

Y Y


Stevia Growers and Processors Need to Develop for The Food Industry to Reach Full

PotentialY Y


5 Stocks with the Catalysts and Opportunity for Large Returns Over the Next Year

Y Y

31


Appendix A


PublishedTitle



Payment (Y/N)



Targeted Radiation Looks to Create and Grow Revenue

Y Y


Small Pharma Sector Leaders Could Make a Profitable Diversified Portfolio

Y Y


Companies Advancing Radiotherapy In Fighting Cancer May Also Deliver Strong Gains

for InvestorsY Y


Companies Gear Up as Health Canada Approves Stevia as Additive for Food and

Beverage UseY Y


Galena Biopharma: Recent Developments Paint A Picture Of The Year Ahead

Y Y

254 2012.12.11 Lidingo (Nichols) The Swiss Trader Lavos/Lidingo ONCSSeeking Alpha

Celsion to Open the Door for Medical Device Companies Following Its Success

Y Y


5 Stocks to Watch in Biotech Y Y

256 2012.12.16 Lidingo Trading Maven Lavos/Lidingo STVFSeeking Alpha

As Stevia Grows in Acceptance, Companies and Investors May Find Sweet Rewards

Y Y

32


Appendix A


PublishedTitle



Payment (Y/N)



Galena Pulls Back While Analysts Rush to its Defense

Y Y


3 Small Pharma Companies with Major Catalysts in 2013

Y Y

259 2012.12.17 Lidingo (Nichols) Sterling, William Lavos/Lidingo ONCSMarket

PlaygroundThree Biopharmaceutical Companies with

Advancing Promising Skin Cancer TreatmentsY N


Galena Removes Financing Risk Y Y


Investments in Novel IL‐12 Administration Platforms in the Fight against Cancer

Y Y

262 2012.12.25 Lidingo A. John Hodge Lavos/Lidingo GALESeeking Alpha

4 Small Biotech Stocks That Should Continue With Large Returns in 2013

Y Y


With Osiris Overvalued, NeoStem Is A Better Buy

Y Y


Successful Infusion of Cancer Treatment May Attract Infusion of Investors in 2013.

Y Y

33


Appendix A


PublishedTitle



Payment (Y/N)



3 Investments in Stevia/Sugar Blends to Mix In With Your Portfolio

Y Y

266 2013.01.14 Ramey, Stephen Chemistfrog Lavos/Lidingo GALE, ADMDSeeking Alpha

'Top of the Class' Small Pharma Investments for 2013

Y Y

267 2013.01.17 Ramey, Stephen Chemistfrog Lavos/Lidingo GALE, NBSSeeking Alpha

Top of the Class Small Pharma Investments for 2013 Part II

Y Y


What Makes for a Market Leading Return in Biotechnology?

Y Y

269 2013.01.22 Lidingo (Nichols) Baldwin, Amy Lavos/Lidingo ONCSMarket

Playground

Oncosec Medical Inc. (ONCS) A Continuous News Stream Could Produce Portfolio‐

Changing GainsY N

270 2013.01.22 Lidingo (Nichols) Teresa Dawn Lavos/Lidingo ADMDSeeking Alpha

Nordion Continues To Prepare Investors For A New‐Look Company

Y Y


Growing Use of Radiopharmaceuticals for Fighting Cancer Shows Promise

Y Y

272 2013.01.29 Lidingo Leopold Epstein Lavos/Lidingo STVFMarket

PlaygroundStevia First (STVF) An Investment in an

Emerging Billion Dollar BusinessY N

34


Appendix A


PublishedTitle



Payment (Y/N)


273 2013.02.04 Ramey, Stephen ChemistfrogDunedin;

Lavos/LidingoONCS

Seeking Alpha

Imminent Catalysts Should Keep Investor Interest Alive For These 3 Pharmaceuticals

Y Y


Investing in Zero‐Calorie Sugar Substitutes May Fatten Investors' Wallets

Y Y


Extending Lives Through Nuclear Medicine May Also Extend Investors' Profits

Y Y


A Comprehensive Look at Immunotherapy With Immunologist Dr. Rahul Jasuja

Y Y


3 Small Cap Radiopharmaceuticals With an Exciting 2013 Ahead

Y Y


3 Cutting Edge Cancer Therapies May Target Investor Portfolios to Yield Gains

Y Y

279 2013.02.12 Writer 1 N/A Lavos/Lidingo STVFSeeking Alpha

What Do Stevia First and Arena Pharmaceuticals Have in Common?

Y Y

280 2013.02.14 Lidingo The Swiss Trader Lavos/Lidingo ONCSInvestor Village

Four Small Biotechs with Big Potential in 2013 Y N

35


Appendix A


PublishedTitle



Payment (Y/N)


281 2013.02.18 Lidingo Sterling, William Lavos/Lidingo ONCSSeeking Alpha

Stocks Could Rise For Companies Investing in Immunotherapy Treatments

Y Y

282 2013.02.18 Lidingo (Nichols) Leopold Epstein Lavos/Lidingo STVFSeeking Alpha

4 Small Caps Seeing Positive Reversals Y Y

283 2013.02.19 Writer 1 N/A Lavos/Lidingo ADMDSeeking Alpha

3 Speculative Healthcare Companies with High Levels of Insider Ownership

Y Y

284 2013.02.19 Writer 5 Dutch Trader Lavos/Lidingo GALESeeking Alpha

Galena: A Small‐Cap Biotech Ready to Fly? Y Y


Diagnosis and Treatment of Disease with Radiotherapies May Prove Profitable in 2013

Y Y


The Monday Morning Quarterback Y Y


5 Speculative Biotech Stocks with Catalysts Pending

Y Y


2012 Stem Cell Standouts and the Outlook for 2013

Y Y

36


Appendix A


PublishedTitle



Payment (Y/N)


289 2013.03.04 Nichols, Brian N/A Lavos/Lidingo GALE, ONCSSeeking Alpha

A Comprehensive Look at Immunotherapy ‐ Part 2

Y Y


3 Speculative Biotech Companies Looking to Reshape the Healthcare Landscape

Y Y

291 2013.03.08 Nichols, Brian N/A Lavos/Lidingo GALE, NBSSeeking Alpha

Seeking Opportunity: Creating a Plan of Investment Action

Y Y


The Weekend Blitz: A Discussion of Investment Strategies and Investment Ideas

Y Y


Cargill Makes a Big Investment in the Future of Stevia

Y Y

294 2013.03.11 Lidingo Sterling, William Lavos/Lidingo GALE, NBSSeeking Alpha

3 Undiscovered Biotech Companies For The Healthcare Investor

Y Y

295 2013.03.11 Writer 5 Dutch Trader Lavos/Lidingo ONCSSeeking Alpha

Looking Back to Alternative Cancer Therapies Y Y

296 2013.03.15 Nichols, Brian N/A Lavos/Lidingo GALE, NBSSeeking Alpha

Seeking Opportunity: 10 Stocks to Watch Right Now

Y Y

37


Appendix A


PublishedTitle



Payment (Y/N)



3 Biotech Stocks That are Set‐Up Nicely for Growth

Y Y


The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays

Y Y

299 2013.03.18 Lidingo Leopold Epstein Lavos/Lidingo STVFSeeking Alpha

Next Generation of Sweetener Market Players Y Y

300 2013.03.18 Lidingo Sterling, William Lavos/Lidingo ONCSSeeking Alpha

3 Companies Developing Novel Cancer Drug Delivery Platforms

Y Y


New Regulations to Phase Out HEU Radioisotopes May Phase In Money for

InvestorsY Y

302 2013.03.18 Lidingo Teresa Dawn Lavos/Lidingo GALESeeking Alpha

3 Immunotherapy Companies that Have Learned Their Lessons Well

Y Y


The Blitz: Are these Stocks Presenting Upside? Y Y

304 2013.03.25 Lidingo Lassiter, Phil Lavos/Lidingo STVFSeeking Alpha

3 Companies with Innovative Mangement Teams to Propel Business Forward

Y Y

38


Appendix A


PublishedTitle



Payment (Y/N)



Galena Biopharma: A Small Cap Looking for Revenues

Y Y


Biotechnology Super Panel Talks Development, Marketing and the Future

Y Y


Recent Melanoma Trial Data Has Biotech Stocks Moving

Y Y


The 'Blitz': Looking at Individual Stocks Presenting Value

Y Y


3 Contenders With Novel, Non‐Invasive Treatments for Cancer

Y Y


Galena Biopharma: Will Developments Continue In 2013?

Y Y

311 2013.04.03 Lidingo Lassiter, Phil Lavos/Lidingo ADMDSeeking Alpha

Medical Isotope Producers Could be Lucrative Investment Ventures

Y Y

312 2013.04.04 Corenman, Joel Woods, Glen S. Lavos/Lidingo APHYSeeking Alpha

Retail Pharmacy Stocks Continue to Rise Despite Stiff Competition

Y Y

39


Appendix A


PublishedTitle



Payment (Y/N)



3 Radiotherapy Companies That Could Make Big Gains in 2013

Y Y


The 9 Levels of Biotechnology And Who Should Invest: Part 2

Y Y


The Vatican/Neostem Partnership Looks to Create Interest and Advance Cell Therapy

Y Y

316 2013.04.11 Cassano, Vincent VFC's Stock House Lavos/Lidingo APHYSeeking Alpha

Stock Watch Thursday, 11 April 2013 Y Y


BSD Medical News to Create a Spark Y Y

318 2013.04.15 Corenman, Joel Woods, Glen S. Lavos/Lidingo APHYSeeking Alpha

Specialty Pharmacies: An Overlooked Segment in a Profitable Industry

Y Y


5 Biotechnology Stocks That Greatly Outperformed the Market in Q1

Y Y


2 Undervalued Immunotherapy Picks Y Y

40


Appendix A


PublishedTitle



Payment (Y/N)


321 2013.04.16 Cassano, Vincent VFC's Stock House Lavos/Lidingo APHYSeeking Alpha

Healthcare Sector Trends May be Shifting Towards Boutique Pharmacy Services

Y Y

322 2013.04.16 Ramey, Stephen Chemistfrog Lavos/Lidingo ADMDMarket

PlaygroundInterview with Advanced Medical Isotope

Corp. (ADMD) CEO James KatzaroffY N

323 2013.04.20 Thornton, Ciaran Stock Investor Lavos/Lidingo ONCSSeeking Alpha

Companies Focused on Cancers of the Epidermal Layers May Yield Profits

Y Y


An Industry Outlook with Analyst Vernon Bernardino

Y Y

325 2013.04.22 Ramey, Stephen Chemistfrog Lavos/Lidingo APHYMarket

PlaygroundAssured Pharmacy ‐ A Possible New Drug

Abuse Deterrence Business ModelY N

326 2013.04.22 Writer 6 EnhydrisPECorp Lavos/Lidingo ADMDSeeking Alpha

Darwinian Selection in Medical Devices: Brachytherapy Offers Investors Hope

Y Y


Melanoma: Battle of 3 Cancer Vaccines Y Y

328 2013.04.25 Lidingo Sterling, William Lavos/Lidingo NBSSeeking Alpha

NeoStem: A Simple Look at Regenerative Medicine

Y Y

41


Appendix A


PublishedTitle



Payment (Y/N)


329 2013.04.28 Corenman, Joel Woods, Glen S. Lavos/Lidingo ENZSeeking Alpha

Could Enzo Biochem’s Intellectual Property Lawsuits Be Worth Billions?

Y Y


5 Stocks To Watch For Gains Next Week Y Y

331 2013.04.28 Thornton, Ciaran Stock Investor Lavos/Lidingo NBSSeeking Alpha

Regenerative Medicine's Time Has Come Y Y


Three Market Trends to Watch Y Y

333 2013.05.01 Writer 5 Dutch Trader Lavos/Lidingo APHYSeeking Alpha

Looking Into the Specialty Pharmacy Sector Y Y


Profits Can Be Found in the Expanding and Challenging Medical Isotope Business

Y Y


5 Stocks To Watch for Gains Next Week Y Y

336 2013.05.06 Lidingo Teresa Dawn Lavos/Lidingo ONCSSeeking Alpha

Companies Developing Targeted Cancer Treatments Seek Higher Profits in 2013

Y Y

42


Appendix A


PublishedTitle



Payment (Y/N)


337 2013.05.06 Writer 6 EnhydrisPECorp Lavos/Lidingo APHYSeeking Alpha

Generalist vs. Specialist Approaches in the Competitive Pharmacy Space

Y Y

338 2013.05.11 Nichols, Brian N/A Lavos/Lidingo ONCS, NBSSeeking Alpha

5 Stocks To Watch For Gains Next Week Y Y

339 2013.05.13 Ramey, Stephen Chemistfrog Lavos/Lidingo ENZSeeking Alpha

Enzo Biochem's Intellectual Property Protection To Attract Investor Attention In

2013Y Y

340 2013.05.13 Thornton, Ciaran Stock Investor Lavos/Lidingo APHYSeeking Alpha

Investing in Pharmacy Stocks Could Be the Next Major Play

Y Y

341 2013.05.14 Meyer, Thomas Equity Options Guru Lavos/Lidingo NBSSeeking Alpha

3 Biotech Stocks With Potential Y Y

342 2013.05.20 Meyer, Thomas Equity Options Guru Lavos/Lidingo ONCSSeeking Alpha

3 Small Cap Cancer Stocks with Upcoming Catalysts

Y Y


A Focus on Stem‐Cell Therapy and Regenerative Medicine for 2013

Y Y

344 2013.05.20 Writer 6 EnhydrisPECorp Lavos/Lidingo STVF Motley FoolWill Stevia Provide a Sweet Return for

Investors?Y N

43


Appendix A


PublishedTitle



Payment (Y/N)


345 2013.05.28 Writer 3 N/A Lavos/Lidingo APHYInvestorsHu

bProposed Legislation Compounds Pharmacy

RisksY N


NeoStem ‐ A Biotech with Lots of Promise Y Y

347 2013.06.03 Meyer, Thomas Jim Taylor Lavos/Lidingo APHYInvesting.co

mPharmaceutical Stocks Continue to

OutperformY N

348 2013.06.05 Writer 3 N/A Lavos/Lidingo STVF MinyanvilleAs Consumers Demand ‘Natural,’ Stevia Set to

Become Blockbuster ProductY N

349 2013.06.06 Ramey, Stephen Chemistfrog Lavos/Lidingo ONCS BenzingaThe Battle of IL‐12 Administration for Cancer

Treatment: Is it Really a Battle?Y N

350 2013.06.10 Writer 3 N/A Lavos/Lidingo APHY MinyanvilleStock Pick: Drug Scares and Pharmacy Security

Create Opportunity for Small PlayerY N

351 2013.06.11 Keolanui, Craig N/A Lavos/Lidingo STVFMarket

PlaygroundCan Stevia Help Soft Drinks Get Past the

Obesity and Diabetes Epidemic?Y N


Oncosec's and Ziopharm's IL‐12 Targeted Delivery Systems: Which Will Succeed?

Y Y

44


Appendix A


PublishedTitle



Payment (Y/N)


353 2013.06.17 Meyer, Thomas T.M. Meyer Lavos/Lidingo ONCS MinyanvilleImmunotherapy: Four Companies on the Verge of Cancer‐Treatment Breakthroughs

Y N


5 Meaningful Upgrades That You Should Note Y Y

355 2013.07.01 Meyer, Thomas T.M. Meyer Lavos/Lidingo NBS MinyanvilleNeoStem Inc.: A Stem Cell Company with an

Attractive ValuationY N

356 2013.07.08 Writer 3 N/A Lavos/Lidingo STVFInvestorsHu

bNew Stevia Extracts – What’s the Reb? Y N


An Overlooked Metric in Biotechnology That You Should Utilize

Y Y


Finally! Electroporation Is Being Noticed By The Street

Y Y


What Does This Reverse Split Mean For Neostem Shareholders?

Y Y

360 2013.07.15 Meyer, Thomas T.M. Meyer Lavos/Lidingo STVF MinyanvilleStevia First Corp Set to Become Leader in Non‐

Caloric Beverage IndustryY N

45


Appendix A


PublishedTitle



Payment (Y/N)



5 Speculative Biotech Stocks With Catalysts Pending: Revisited

Y Y


NeoStem Announces Several Key Milestones That Should Excite Investors

Y Y


Neostem ‐ Great Reverse‐Split Activity, But What's Next?

Y Y

364 2013.07.26 Writer 3 N/A Lavos/Lidingo ONCS MinyanvilleNew Analytic Tools Fuel Growth in Personal

MedicineY N

365 2013.07.30 Meyer, Thomas T.M. Meyer Lavos/Lidingo ONCS MinyanvilleBiotech Stocks Continue to See Share Prices

Jump on CatalystsY N


Great Leadership and Massive Opportunities Make This Hire Terrific

Y Y

367 2013.08.01 Meyer, Thomas T.M. Meyer Lavos/Lidingo GALE MinyanvilleBiotech Stocks: Breast Cancer Drugs in Clinical

Trials Offer New HopeY N

368 2013.08.05 Writer 3 N/A Lavos/Lidingo STVF MinyanvilleCoca‐Cola and Pepsi: Facing Slower Sales, Big Soda is Testing Stevia in Sample Markets

Y N

46


Appendix A


PublishedTitle



Payment (Y/N)


369 2013.08.05 Keolanui, Craig N/A Lavos/Lidingo NBSSeeking Alpha

NeoStem: A Stem Cell Leader Making All the Right Moves

Y Y


NeoStem's Athelos Could Begin Garnering Attention

Y Y


2 Biotechs Aim To Capitalize on the Treatment of Melanoma

Y Y


Galena Biopharma: Best and Worst Case Scenario

Y Y


Could Baxter Acquire This Small Company? Y Y


CocaCola's Gamble on Coke Life May have Other Bottlers Scrambling for a Better Tasting

SteviaY Y


With Vical Out, What's Next For The Melanoma Pipeline?

Y Y


Seeking the Best Opportunities in Biotech by Value

Y Y

47


Appendix A


PublishedTitle



Payment (Y/N)



Galena Biopharma, Ready for A Jump? Y Y

378 2013.08.29 Writer 3 AlphaVN Securities Lavos/Lidingo ONCSSmallCapNe

tworkImmunotherapy Broadens Hope for Patients

and InvestorsY N

379 2013.09.03 Meyer, Thomas N/A Lavos/Lidingo NBSWall Street Cheat Sheet

4 Reasons NeoStem May See Significant Share Price Appreciation

Y N

380 2013.09.03 Lidingo/Hodge Kawabe, Henry Lavos/Lidingo STVFSeeking Alpha

Coca‐Cola Makes Serious Changes To Stay On Top

Y Y

381 2013.09.04 Lidingo/Hodge A. John Hodge Lavos/Lidingo ONCSSeeking Alpha

4 Biotechs with Catalysts Looming Y Y

382 2013.09.04 Lidingo/Hodge Baldwin, Amy Lavos/Lidingo GALESeeking Alpha

3 Biotech Products to Watch Over the Next Year

Y Y


NeoStem And Neuralstem: 2 Early Regenerative Medicine Winners

Y Y

384 2013.09.11 Meyer, Thomas N/A Lavos/Lidingo GALEWall Street Cheat Sheet

2 Small Cap Biotechnology Stocks with Big Promise

Y N

48


Appendix A


PublishedTitle



Payment (Y/N)


385 2013.09.11 Lidingo Teresa Dawn Lavos/Lidingo GALESeeking Alpha

Inovio's Partnership and its Many Benefits Y Y

386 2013.09.12 Nichols, Brian Arthur Rhodes Lavos/Lidingo ONCSMarket

PlaygroundOncoSec: A Presentation of Catalysts Y N

387 2013.09.12 Corenman, Joel Woods, Glen S. Lavos/Lidingo NBSSeeking Alpha

Novartis and NeoStem: Developing Therapies to Extend the Quality of Life for Heart Disease

PatientsY Y

388 2013.09.16 Writer 3 AlphaVN Securities Lavos/Lidingo GALESmallCapNe

tworkImmunotherapies Extend Effectiveness of

Standard CareY N

389 2013.09.16 Corenman, Joel Woods, Glen S. Lavos/Lidingo STVFSmallCapNe

twork

New Method of Producing Stevia May Challenge the Entire $10 Billion Sugar

Substitute MarketY N


Neostem Continues To Soar Behind A Slew Of Key Developments

Y Y

391 2013.09.19 Meyer, Thomas N/A Lavos/Lidingo NBSThestreet.c

omNeoStem To Reach Its Real Value By Year End Y N


3 Companies On The Forefront Of Cancer Immunotherapy Innovations

Y Y

49


Appendix A


PublishedTitle



Payment (Y/N)



Coca‐Cola's Move to Stevia: Don't Rush. . . But Move Quickly

Y Y

394 2013.09.27 Lidingo/Hodge The Swiss Trader Lavos/Lidingo LBIOSeeking Alpha

3 Companies Developing the Future of Cancer Therapy

Y Y


Galena Biopharma: What Now? Y Y


NeoStem: An Investment In 4 Different Divisions

Y Y

397 2013.10.01 Meyer, Thomas N/A Lavos/Lidingo ONCSWall Street Cheat Sheet

3 Small‐Cap Biotechnology Stocks Making Big Moves

Y N

398 2013.10.02 Nichols, Brian N/A Lavos/Lidingo LBIOSeeking Alpha

Investing Smart: Biotechs, Effective Therapies and Shareholder‐Friendly CEOs

Y Y


Companies Race to Develop the Next Novel Blockbuster Diabetes Drug – Part 2

Y Y

400 2013.10.06 Lidingo/Hodge Baldwin, Amy Lavos/Lidingo GALESeeking Alpha

Celebrating Breast Cancer Awareness With A Great Year of Clinical Breakthroughs

Y Y

50


Appendix A


PublishedTitle



Payment (Y/N)


401 2013.10.07 Ramey, Stephen Chemistfrog Lavos/Lidingo ONCS BenzingaOncoSec Medical to Wrap Up 2013 with

Multiple Possible CatalystsY N


4 Companies You Must Watch Regardless of Market Performance

Y Y

403 2013.10.15 Meyer, Thomas James Ratz Lavos/Lidingo STVFWall Street Cheat Sheet

Three Companies Fighting to Stop Obesity Y N


This Short‐Term Pain Might be Best for Long‐Term Gain

Y Y

405 2013.10.15 Thornton, Ciaran Stock Investor Lavos/Lidingo GALESeeking Alpha

Will Lost Patents Force Roche into Acquisition Mode?

Y Y

406 2013.10.18 Lidingo The Swiss Trader Lavos/Lidingo LBIOSeeking Alpha

5 Companies Race To Develop The Next Great Melanoma Product

Y Y

407 2013.10.21 Writer 3 AlphaVN Securities Lavos/Lidingo ONCSSmallCapNe

tworkNew Broad Steps Forward in Cancer Drugs Y N


Celgene and Neostem: 2 Biopharmaceutical Companies Poised for Growth

Y Y

51


Appendix A


PublishedTitle



Payment (Y/N)


409 2013.10.22 Nichols, Brian N/A Lavos/Lidingo GALE Motley FoolDo Low Expectations Set the Stage for Large

Post‐Launch GainsY N


Coke's Future Remains Uncertain, While Pepsi Continues to Thrive

Y Y


Four Biotech Stocks Making Headlines Y N


Investments in Targeting HER2 for the Treatment of Cancer

Y Y

413 2013.10.28 Thornton, Ciaran Buy Sell Short Lavos/Lidingo STVF BenzingaExamining Healthier Options in Our Diets and

InvestmentsY N


Biotechnology: Finding the Best and Worst Value in the Industry

Y Y

415 2013.10.30 Lidingo/Hodge The Swiss Trader Lavos/Lidingo NBSSeeking Alpha

NeoStem: Major Developments You Might Have Missed

Y Y

416 2013.10.31 Nichols, Brian N/A Lavos/Lidingo LBIO

Seeking Alpha

Instablog Sub‐Site

Singh Secures Lion for 2 Years & Prepares for Uplisting

Y N

52


Appendix A


PublishedTitle



Payment (Y/N)


417 2013.11.02 Lidingo A. John Hodge Lavos/Lidingo GALESeeking Alpha

5 Short‐Term Catalysts Make Galena a Long‐Term Buy

Y Y


tworkMillennials: The Driving Force Behind Stevia’s

Growth?Y N


Three Promising Biotech Stocks with Upcoming Catalysts

Y N

420 2013.11.05 Thornton, Ciaran Stock Investor Lavos/Lidingo ONCSSmallCapNe

tworkAn Investment in Biotech: Searching for the

Next Big Cancer PlayY N

421 2013.11.07 Nichols, Brian N/A Lavos/Lidingo GALE Motley FoolHas the Next Insys Therapeutics Been

Identified?Y N


Investing in Companies Targeting Millennials Should Prove Profitable

Y Y

423 2013.11.12 Meyer, Thomas James Ratz Lavos/Lidingo GALEWall Street Cheat Sheet

Will Galena Biopharma Triple Soon? Y N


Combination Therapies Hold Key To Future Cancer Treatments

Y Y

53


Appendix A


PublishedTitle



Payment (Y/N)



Exciting Stem Cell Investment Candidates With Near‐Term Catalysts

Y Y


Treating Melanoma: Only The Best Shall Survive

Y Y

427 2013.11.14 Meyer, Thomas N/A Lavos/Lidingo LBIOWall Street Cheat Sheet

3 Biotechnology Stocks in the Cancer Space with Strong Growth Potential

Y N


tworkInvesting in Companies Developing Promising

Immunotherapy Drugs for MelanomaY N

429 2013.11.18 Meyer, Thomas James Ratz Lavos/Lidingo STVFWall Street Cheat Sheet

Stevia First Surges in Anticipation of Commercial Launch

Y N

430 2013.11.22 Meyer, Thomas Matt Levy Lavos/Lidingo GALEWall Street Cheat Sheet

Positive Trial Data Sends Galena Biopharma Shares Higher

Y N


Companies Advancing Stem Cell Therapies Could Also Advance Your Portfolio Dollars

Y Y


Oncosec Medical Leading the Charge Against Skin Cancer

Y N

54


Appendix A


PublishedTitle



Payment (Y/N)



Lion Biotechnologies: 3 Bullish Reasons Why I Like this Speculative Biotech

Y Y


S & W Seed Company: Avoiding What Should Be Its Main Focus

Y Y

435 2013.11.27 Writer 4 Stock Whisper Lavos/Lidingo GALESeeking Alpha

Galena: More Reasons to Buy Y Y

436 2013.12.01 Lidingo/Hodge Lassiter, Phil Lavos/Lidingo ARTHSeeking Alpha

Medical Device Companies with Big Growth Potential

Y Y

437 2013.12.02 Meyer, Thomas Matt Levy Lavos/Lidingo STVFWall Street Cheat Sheet

3 Healthy Foods Companies that Will Make your Portfolio Green

Y N

438 2013.12.02 Meyer, Thomas N/A Lavos/Lidingo LBIOWall Street Cheat Sheet

2 Biotech Stocks Facing Major Catalysts in 2014

Y N

439 2013.12.02 Thornton, Ciaran Stock Investor Lavos/Lidingo GALESeeking Alpha

Galena: A Pipeline Rich for Investors Y Y

440 2013.12.02 Thornton, Ciaran Stock Investor Lavos/Lidingo ONCSSeeking Alpha

Fighting Back against the Growing Threat of Melanoma

Y Y

55


Appendix A


PublishedTitle



Payment (Y/N)


441 2013.12.09 Corenman, Joel Woods, Glen S. Lavos/Lidingo LBIOSeeking Alpha

4 Companies Developing Blockbuster Immunotherapies to Fight Cancer

Y Y


tworkStevia First Corp. Gears Up for Sales in 2014 Y N


NeoStem: A Stem Cell Company Worth Watching

Y N

444 2013.12.10 Meyer, Thomas Ted Mayer Lavos/Lidingo GALE Motley FoolInvestment Funds are Taking a Big Stake in

Galena BiopharmaY N


3 Breast Cancer Drugs That Could Boost Your Portfolio

Y Y


Coke Life’s Possible U.S. Debut Should Bolster Coca‐Cola and Stevia Sales

Y Y

447 2013.12.16 Writer 5 Dutch Trader Lavos/Lidingo ARTH

Seeking Alpha


Arch Therapeutics, A Promising New Life Science Company

Y Y

448 2013.12.16 Writer 5 Dutch Trader Lavos/Lidingo ARTHSmallCapNe

tworkArch Therapeutics, A Promising New Life

Science CompanyY N

56


Appendix A


PublishedTitle



Payment (Y/N)


449 2013.12.16 Meyer, Thomas N/A Lavos/Lidingo GALE Forbes.comHope for Breast Cancer Patients is Around the

CornerY N

450 2013.12.17 Meyer, Thomas Matt Levy Lavos/Lidingo NBSWall Street Cheat Sheet

NeoStem: Final Data is Just Around the Corner Y N


The Race to Treat Stage III Melanoma Just Got a Lot More Interesting

Y Y


Why is Complete Enrollment Important to Neostem Investors?

Y Y


Will Galena's Post‐Holiday Charm Continue? Y Y


4 Stocks In 4 Industries That Could Make Significant Gains In 2014

Y Y

455 2013.12.23 Thornton, Ciaran Stock Investor Lavos/Lidingo ONCS

Seeking Alpha


Melanoma Biotech Player to Consider: OncoSec Medical (insta‐blog)

Y N


NeoStem Stands To Benefit From Stem‐Cell Deals

Y Y

57


Appendix A


PublishedTitle



Payment (Y/N)



OncoSec Medical Poised for Exciting 2014 Y N

458 2013.12.30 Thornton, Ciaran Itradethebios Lavos/Lidingo ARTHSmallCapNe

tworkA Revolutionary Blood Loss Product Y N

459 2013.12.30 Lidingo Elias Hertz Lavos/Lidingo STVFSmallCapNe

tworkInvesting in Companies Sweetening the Mid‐

Calorie Beverage MarketY N

460 2013.12.31 Writer 4 Stock Whisper Lavos/Lidingo NBSSeeking Alpha

Cellular Therapy: Representing Paradigm Shift in Healthcare

Y Y


4 Stocks that Could See Significant Gains in 2014

Y Y


Is Barron's Right Or Wrong in Predicting 20 % Upside in Coke?

Y Y


tworkHemostasis Products‐A New Growth Market Y N


4 Companies That Should Profit From Consumer Health Trends in 2014

Y Y

58


Appendix A


PublishedTitle



Payment (Y/N)


465 2014.01.13 Meyer, Thomas Kingmaker Lavos/Lidingo ONCSSeeking Alpha

Unique Treatment Approaches Coming for Skin Cancer

Y Y

466 2014.01.13 Meyer, Thomas James Ratz Lavos/Lidingo NBSWall Street Cheat Sheet

Two Innovative Biotech Companies that Could Soar in 2014

Y N

468 2014.01.14 Meyer, Thomas N/A Lavos/Lidingo GALEWall Street Cheat Sheet

Buying Opportunity in OncoSec Medical as Catalysts Approach

Y N

469 2014.01.15 Meyer, Thomas Christine Andrews Lavos/Lidingo GALEWall Street Cheat Sheet

The Momentum Continues for Galena Biopharma

Y N

470 2014.01.15 Lidingo/Hodge The Swiss Trader Lavos/Lidingo LBIOSeeking Alpha

Are Modified T‐Cells A Game Changer in Treating Cancer?

Y Y

471 2014.01.20 Writer 5 Dutch Trader Lavos/Lidingo ARTHSmallCapNe

tworkArch Therapeutics, Where to Go From Here? Y N

472 2014.01.20 Writer 5 Dutch Trader Lavos/Lidingo ARTH

Seeking Alpha


Arch Therapeutics, Where to Go From Here? Y N

473 2014.01.20 Thornton, Ciaran Stock Investor Lavos/Lidingo GALESmallCapNe

tworkInsys Therapeutics ‐ A RoadMap for Galena

Biopharma in 2014Y N

59


Appendix A


PublishedTitle



Payment (Y/N)



3 Small Biotech Companies Poised for Big Growth in 2014

Y Y

475 2014.01.21 Nichols, Brian N/A Lavos/Lidingo ONCSWall Street Cheat Sheet

Electroporation: Looking Ahead at 2014 Y N


NeoStem's AMR‐001 Has Strong Chance of Success

Y N


Investing in Companies that Will Profit from the Growing Healthier Food Market

Y Y


Could PCT Be Neostem's Breakout Star? Y Y


Oncosec Executives Talk Electroporation, PD‐1 Checkpoint Inhibitors, and the Unmet Need In

Immune OncologyY Y


Contract Manufacturing: Often Ignored, but Potentially Profitable

Y Y


Combination Therapies: Where Immuno‐Oncology Is Headed And How To Invest

Y Y

60


Appendix A


PublishedTitle



Payment (Y/N)


483 2014.02.10 Corenman, Joel Woods, Glen S. Lavos/Lidingo LBIOSeeking Alpha

2 Young 'Cats' of Biotech Poised to Climb Higher in 2014

Y Y


Is There Investment Upside in the Future of Treating Diabetes?

Y Y


tworkFinding Possible Investment Candidates at

Equity ConferencesY N

486 2014.02.17 Nichols, Brian N/A Lavos/Lidingo ONCSWall Street Cheat Sheet

Big Pharma Continues the Race for Electroporation

Y N

487 2014.02.18 Meyer, Thomas John Rivers Lavos/Lidingo NBSWall Street Cheat Sheet

Immune Checkpoint Blocker Race Heats Up Y N

488 2014.02.18 Meyer, Thomas John Rivers Lavos/Lidingo GALEWall Street Cheat Sheet

Three Great Small Cap Biotech Stocks: Neostem, Pozen, Curis

Y N


2 Cell Therapy Companies that Could Thrive with Cardiovascular Disease

Y Y


Modified T‐Cells: Quietly Becoming Very Relevant

Y Y

61


Appendix A


PublishedTitle



Payment (Y/N)



NeoStem: a Potential Blockbuster for Investors

Y N

492 2014.03.10 Writer 5 Dutch Trader Lavos/Lidingo ARTHSeeking Alpha

Arch Therapeutics and the Advance Wound Market

Y Y


Zeiher Study Likely Predicts the Outcome of Neostem's AMR‐001 Trial

Y Y


Is OncoSec Medical Set to Trade Even Higher? Y Y

62


case 1:17-cv-02540 document 1-1 filed 04/10/17 page 1 of ... · appendix a # date writer/publisher...

Documents